Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED)

v3.8.0.1
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED) - 6 months ended Apr. 30, 2018 - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total Shareholders Equity [Member]
Noncontrolling Interest [Member]
Total
Balance at Oct. 31, 2017 $ 166,028 $ 163,931,079 $ (156,174,184) $ 7,922,923   $ 7,922,923
Balance (in Shares) at Oct. 31, 2017 16,602,759          
Stock option compensation to employees and directors   472,532   472,532   472,532
Stock option compensation to consultants   126,151   126,151   126,151
Common stock issued upon exercise of stock options $ 398 (398)        
Common stock issued upon exercise of stock options (in Shares) 39,816          
Common stock issued to consultants $ 53 14,949   15,002   15,002
Common stock issued to consultants (in Shares) 5,347          
Common stock issued in at-the-market offering $ 2,025 675,345   677,370   677,370
Common stock issued in at-the-market offering (in Shares) 202,523          
Issuance of noncontrolling interest in Certainty Therapeutics, Inc   68,974   68,974 $ (4,318) 64,656
Net loss     (3,216,606) (3,216,606) (41,382) (3,257,988)
Balance at Apr. 30, 2018 $ 168,504 $ 165,288,632 $ (159,390,790) $ 6,066,346 $ (45,700) $ 6,020,646
Balance (in Shares) at Apr. 30, 2018 16,850,445